Vaccination with minigenes encoding for novel 'self' antigens are effective in DNA-vaccination against neuroblastoma

Cancer Letters

Volumn 197, Issue 1-2, 2003, Pages 211-217

  Huebener, N ^a   Lange, B ^a   Lemmel, C ^b   Rammensee, H G ^b   Strandsby, A ^a   Wenkel, J ^a   Jikai, J ^a   Zeng, Y ^a   Gaedicke, G ^a   Lode, H N ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Antigen presenting cells; DNA vaccines; Immunogenicity; Immunotherapy; Minigene; Neuroblastoma; Salmonella typhimurium; T cell response; Therapy; Tolerance

Indexed keywords

ASPARAGINYLGLUTAMYLTYROSYLISOLEUCYLMETHIONYLSERYLLEUCYLISOLEUCINE; DNA VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PHENYLALANYLGLUTAMYLMETHIONYLVALYLSERYLTHREONYLLEUCYLISOLEUCINE; PROTEASOME; THREONYLGLUTAMYLALANYLLEUCYLPROLYLVALYLLYSYLLEUCYLISOLEUCINE; TUMOR ANTIGEN; TUMOR VACCINE; UBIQUITIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; BACTERIAL STRAIN; BINDING AFFINITY; CANCER CHEMOTHERAPY; CANCER PREVENTION; CELL STRAIN; CONFERENCE PAPER; CONTROLLED STUDY; DNA CLEAVAGE; DRUG EFFICACY; ELUTION; EXPRESSION VECTOR; GENE CONSTRUCT; GENETIC CODE; IMMUNOPRECIPITATION; MAMMAL; MOLECULAR CLONING; MOUSE; NEUROBLASTOMA; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; SALMONELLA TYPHIMURIUM; SEPARATION TECHNIQUE; TANDEM MASS SPECTROMETRY; TUMOR IMMUNITY; UPREGULATION; VACCINATION;

MAMMALIA; MURINAE; SALMONELLA TYPHIMURIUM; TYPHIMURIUM;

EID: 0037767706     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00102-2     Document Type: Conference Paper

References (11)

1. Blankenstein T., Cayeux S., Qin Z. Genetic approaches to cancer immunotherapy. Rev. Physiol. Biochem. Pharmacol. 129:1996;1-49.
2. Fong L., Engleman E.G. Dendritic cells in cancer immunotherapy. Annu. Rev. Immunol. 18:2000;245-273.
3. Egen J.G., Kuhns M.S., Allison J.P. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 7:2002;611-618.
4. Haupt K., Roggendorf M., Mann K. The potential of DNA vaccination against tumor-associated antigens for antitumor therapy. Exp. Biol. Med. 227:2002;227-237.
5. Dietrich G., Spreng S., Gentschev I., Goebel W. Bacterial systems for the delivery of eukaryotic antigen expression vectors. Antisense Nucleic Acid Drug Dev. 10:2000;391-399.
6. Cochlovius B., Stassar M.J., Schreurs M.W., Benner A., Adema G.J. Oral DNA vaccination: antigen uptake and presentation by dendritic cells elicits protective immunity. Immunol. Lett. 80:2002;89-96.
7. Ismail N., Olano J.P., Feng H.M., Walker D.H. Current status of immune mechanisms of killing of intracellular microorganisms. FEMS Microbiol. Lett. 207:2002;111-120.
8. Lode H.N., Pertl U., Xiang R., Gaedicke G., Reisfeld R.A. Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma. Med. Pediatr. Oncol. (35):2000;641-646.
9. Rock K.L., York I.A., Saric T., Goldberg A.L. Protein degradation and the generation of MHC class I-presented peptides. Adv. Immunol. 80:2002;1-70.
10. Rodriguez F., Zhang J., Whitton J. DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J. Virol. 71:1997;8497-8503.
11. Lode H.N., Xiang R., Varki N.M., Dolman C.S., Gillies S.D., Reisfeld R.A. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J. Natl. Cancer Inst. 89:1997;1586-1594.